Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.

Journal of medical virology - 1 Jun 2021

Du Jialiang, Gu Qiong, Liu Yan, Li Qiming, Guo Tai, Liu Yueyue

Abstract excerpt

Norovirus-like particle (VLP) vaccine is promising against human norovirus infection. Unfortunately, genetic diversity of norovirus hindered the development of this vaccine. In this study, the immunogenicity of norovirus VLPs induced by the endemic GII.4 and the epidemic GII.17 genotypes, and the cross-reactivity between them as well as GI.1 and GII.3 VLPs were evaluated in mice by using serum IgG and histo-blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Caliciviridae Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross Reactions

Share to Endemic Diseases

Share to Gastroenteritis

Share to Norovirus

Share to Specific Pathogen-Free Organisms

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 32869863
DOI: 10.1002/jmv.26474
PMCID: PMC8246737

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.PMID 32869863Read ↗

Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.Semantic proximity Read ↗

Receptor profile and immunogenicity of the non-epidemic norovirus GII.8 variant.Semantic proximity Read ↗

Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccineSemantic proximity Read ↗

Characterization of high affinity IgM and IgG monoclonal antibodies against norovirus variants GII.4 and GII.17Semantic proximity Read ↗

Identification of a blockade epitope of human norovirus GII.17.Semantic proximity Read ↗

Genetic analyses of GII.17 norovirus strains in diarrheal disease outbreaks from December 2014 to March 2015 in Japan reveal a novel polymerase sequence and amino acid substitutions in the capsid region.Semantic proximity Read ↗

Chimeric VLPs with GII.3 P2 domain in a backbone of GII.4 VP1 confers novel HBGA binding ability.Semantic proximity Read ↗

Characterization of the new GII.17 norovirus variant that emerged recently as the predominant strain in ChinaSemantic proximity Read ↗

Biological and immunological characterization of major capsid protein VP1 from distinct GII.2 norovirus clusters.Semantic proximity Read ↗

Expression and characterization of the major capsid protein derived from a GII.6 norovirus strain isolated in China.Semantic proximity Read ↗

Development of a broad-spectrum therapeutic Fc-nanobody for human norovirusesSemantic proximity Read ↗

Characterization of virus-like particles derived from a GII.3 norovirus strain distantly related with current dominating strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.